ClinicalTrials.gg
Not yet recruitingNCT07785531Updated Aug 25, 2026

Risk Factors, Etiology and Predictable Outcomes With Risk Stratification Scores in Acute Heart Failure Patients

An observational study in Acute Heart Failure (AHF), sponsored by Assiut University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Assiut University · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
350
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies in Heart Failure by Assiut University — 12 open to participants now, 12 under way, none of them phase 3. Heart Failure · Assiut University.

Planned enrollment
Largest of 20
350 · median 100
Started
2026
with 4 others
Observational
20 of 23
11 open now
Primary completion
2028-08
later than 11 of 11 live
Registered
19th of 23
by date

Among the 23 studies in Heart Failure by Assiut University, this one has the largest planned enrollment of the 20 observational ones that give a count, is one of 5 that started in 2026, is one of 20 observational ones, reaches primary completion later than 11 of the 11 other live ones, and was the 19th registered.

Heart Failure

6,332 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.

Browse Heart Failure studies →

Open to participants now

12 of the 23 studies in Heart Failure by Assiut University are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Heart Failure by Assiut University, or all of them as a file.
02

Study summary

Clinical Characteristics, Etiology, Short-Term Outcomes, and Performance of Contemporary Risk Stratification Scores in Acute Heart Failure Patients Presenting to Assiut University Heart Hospital.

Read the detailed description

Primary Aim To characterize the demographic and clinical characteristics, etiological spectrum, precipitating factors, management, and short-term outcomes, including length of stay, ICU admission, organ failure, and 30-day rehospitalization, of patients presenting with acute heart failure at Assiut University Heart Hospital

.Secondary Aim To evaluate the prognostic performance of the HEARTRISK6 score by externally validating its ability to predict short-term adverse outcomes, including in-hospital mortality.

03

Conditions studied

  • Acute Heart Failure (AHF)

Browse trials for

Keywords

  • Risk stratification scores
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Acute heart failure patients presenting to Emergency Department and Cardiology Department, Assiut University Hospitals, Egypt.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age more than 18yrs
  • Clinical diagnosis of acute heart failure according to current ESC guideline criteria.

Exclusion criteria

Exclusion Criteria:

  • Age below than 18
  • Refusal to participate.
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
350 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testEcho

    Echo for clinical assessment

  • Diagnostic testEcg

    Twelve leads ECG to detect any ischemic changes

  • Diagnostic testCreatinine

    To detect renal function test

  • Diagnostic testTroponin

    Ischemic changes

06

What researchers measure

Primary outcomes

  1. Clinical Characteristics, Etiology, Short-Term Outcomes, and Performance of Contemporary Risk Stratification Scores in Acute Heart Failure Patients Presenting to Assiut University Heart Hospital.

    To externally validate the HEARTRISK6 score and evaluate its predictive performance for short-term adverse outcomes in patients with acute heart failure. History of moderate/severe valvular heart disease\_Yes. 1 Heart rate \>100 to ≤120 bpm. 2 \>120 bpm. 3 Non-invasive ventilation (NIV)BiPAP/NIV within first hour 2 Creatinine \>150 to ≤300 µmol/L 2 \>300 µmol/L. 3 Troponin \>3-5 × upper reference limit (URL) 1 \>5 × URL. 2 Failed reassessment / 3-minute walk test ifFailed1 comp0 High score means worse

    Time frame: Follow up patients for 30 days

07

Study locations

1 site
08

References and documents

Publications

  • McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368. No abstract available. PubMed 34447992 ↗

Individual participant data

Plan to share: Yes

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Aug 2028, 24 months later.

Of 794 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 99. This study's planned 24 months is below that.

Counting every sponsor, half of 976 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2026
First posted
Aug 25, 2026
StartEst.
Aug 2026
Primary completionEst.
Aug 2028
CompletionEst.
Sep 2028
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07785531
Lead sponsor
Assiut University
Responsible party
Remoon Hana Henein Mansour (Resident, Assiut University) — Principal investigator
First posted
Aug 25, 2026
Start date
Aug 2026 (estimated)
Primary completion
Aug 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Aug 25, 2026

Study contacts

Remoon hana Mansour
Contact
Remon.18313629@med.aun.edu.eg
+201284555676

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion